The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Cognitive Function as a Predictor of Survival in Patients With Recurrent Malignant Glioma
Abstract
PURPOSE: To determine the contribution of cognitive function in predicting the survival of patients with recurrent malignant brain tumors. PATIENTS AND METHODS: A total of 80 patients with recurrent glioblastoma multiforme or anaplastic astrocytoma were seen for baseline evaluations before beginning a phase I or phase II clinical trial. Each patient received a battery of nine brief tests measuring cognitive function, ability to perform activities of daily living (ADLs), and quality of life (QOL). Tests were given monthly after treatment was begun. RESULTS: Performance on a test of verbal memory was independently and strongly related to survival after accounting for age, Karnofsky performance status score, histology, and time since diagnosis. Models incorporating three of nine and all nine tests in the battery accounted for significantly more variance in survival than did the clinical variables alone. Measures of QOL and ADLs (bathing, feeding, and so on) were not independently related to survival, although they provide clinical information that is important for patient care. CONCLUSION: These results indicate that a multifaceted assessment of cognition, QOL, and patient function is practical for brain tumor patients in clinical trials and can provide information regarding the relative risks versus benefits of new treatment regimens that supplements the information from the usual clinical variables.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
A note on a general definition of the coefficient of determination
NAGELKERKE, N. J. D. (1991) · Biometrika · doi:10.1093/biomet/78.3.691 · Cited by 5,927
Benedict, R. H. B., Schretlen, D., Groninger, L., & Brandt, J. (1998) · The Clinical Neuropsychologist · doi:10.1076/clin.12.1.43.1726 · Cited by 1,597
The structure and stability of the functional independence measure
Linacre, J. M., Heinemann, A. W., Wright, B. D., Granger, C. V., & Hamilton, B. B. (1994) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/0003-9993(94)90384-0 · Cited by 1,274
Measurement in Neurological Rehabilitation
Cole, M. (1993) · Neurology · doi:10.1212/wnl.43.2.459-b · Cited by 1,011
A note on the generalized information criterion for choice of a model
ATKINSON, A. C. (1980) · Biometrika · doi:10.1093/biomet/67.2.413 · Cited by 262
Scheibel, R., Meyers, C., & Levin, V. (1996) · Journal of Neuro-Oncology · doi:10.1007/bf00177444 · Cited by 194
Self-citationCognitive functioning in long-term survivors of high-grade glioma
Archibald, Y. M., Lunn, D., Ruttan, L., Macdonald, D., Maestro, R. F. D., Barr, H. W. K., Pexman, J. H. W., Fisher, B. J., Gaspar, L. E., & Cairncross, J. G. (1994) · Journal of neurosurgery · doi:10.3171/jns.1994.80.2.0247 · Cited by 157
Recording neurological impairment in clinical trials of glioma
Grant, R., Slattery, J. M. A., Gregor, A., & Whittle, I. R. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01051047 · Cited by 62
Neurotoxicity of CI-980, a novel mitotic inhibitor.
Meyers, C. A., Kudelka, A. P., Conrad, C. A., Gelke, C. K., Grove, W. R., & Pazdur, R. (1997) · PubMed · Cited by 38
Self-citation(1995) · doi:10.1002/1097-0142(19950301)75:5<1151::aid-cncr2820750515>3.0.co;2-q
Cited by
Brown, P. D., Pugh, S., Laack, N. N., Wefel, J. S., Khuntia, D., Meyers, C., Choucair, A., Fox, S., Suh, J. H., Roberge, D., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not114 · Cited by 958
Self-citationBrain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium
Bondy, M. L., Scheurer, M. E., Malmer, B., Barnholtz-Sloan, J. S., Davis, F. G., Il'yasova, D., Kruchko, C., McCarthy, B. J., Rajaraman, P., Schwartzbaum, J. A., et al. (2008) · Cancer · doi:10.1002/cncr.23741 · Cited by 932
Cognitive deficits in adult patients with brain tumours
Taphoorn, M. J., & Klein, M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00680-5 · Cited by 756
The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials
Gotay, C. C., Kawamoto, C. T., Bottomley, A., & Efficace, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3439 · Cited by 644
Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species
Montay-Gruel, P., Acharya, M. M., Petersson, K., Alikhani, L., Yakkala, C., Allen, B. D., Ollivier, J., Petit, B., Jorge, P. G., Syage, A. R., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901777116 · Cited by 599
Metadata
- Authors
- Meyers, C. A., Hess, K. R., Yung, W. K. A., & Levin, V. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-02-01
- Volume
- 18
- Issue
- 3
- Pages
- 646-646
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1954477830
- Cited by
- 271
- References
- 11
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.